AMVUTTRA

Generic Name/API: Vutrisiran

Manufacturer: Alnylam Pharmaceuticals, Inc.

Packaging: 1 x 25mg single-dose prefilled syringe

Strength: 25 mg/0.5 mL in a single-dose prefilled syringe

Storage: Store at 2°C to 30°C (36°F to 86°F)

  • INDICATION
  • IMPORTANT SAFETY INFORMATION

INDICATIONS
What is AMVUTTRA?
AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.

IMPORTANT SAFTEY INFORMATION
What are the most important things I should know about AMVUTTRA® (vutrisiran)?
AMVUTTRA can cause:

Low Vitamin A Levels
Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.
What are the common side effects of AMVUTTRA?
The most common side effects of AMVUTTRA are pain in the arms or legs, pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Scroll to Top